News - Arena Pharmaceuticals, lorcaserin

Filter

Popular Filters

Eureka moment: US FDA approves first new obesity drug in 13 years

28-06-2012

After several years of investigation, and a rejection by the US regulator, the Food and Drug Administration…

Arena PharmaceuticalsBelviqEisailorcaserinMetabolicsNorth AmericaPharmaceuticalRegulation

Arena Pharma gets positive FDA panel vote for obesity drug; prophylactic Truvada backed

11-05-2012

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) and Japanese licensing partner Eisai (TYO: 4523) got a…

Anti-viralsArena PharmaceuticalsBiotechnologyEisaiGilead ScienceslorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalRegulationTruvada

Arena Pharma updates on lorcaserin filings in EU and USA

27-03-2012

San Diego, USA-based Arena Pharmaceuticals (Nasdaq: ARNA) revealed yesterday that the European Medicines…

Arena PharmaceuticalsEisaiEuropelorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalRegulation

FDA updates on obesity drug candidates

11-01-2012

There have been two pieces of positive news coming out of the US Food and Drug Administration this week…

Arena PharmaceuticalsEisailorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

Arena files complete response on lorcaserin

05-01-2012

In another attempt to gain approval for its obesity drug candidate that was turned down by US regulators…

Arena PharmaceuticalsEisailorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalRegulationResearch

Arena and Eisai release data on obesity drug candidate lorcaserin to be used in CRL response

03-08-2011

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) and Japanese partner Eisai (TYO: 4523) announced the completion…

Arena PharmaceuticalsEisailorcaserinMetabolicsPharmaceuticalResearch

Back to top